Tak Paul Peter
Chief Executive Officer
Tak Paul Peter has filed 1 SEC Form 4 filing (3 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Sep 11, 2026.
On the most recent filing, Tak Paul Peter is listed as Chief Executive Officer at Candel Therapeutics, Inc. Inside the rolling window, Tak Paul Peter reported no open-market purchases and 2 open-market sales totaling $3.2M in CADL. The largest disclosed transaction in the window is a sale of 220,866 CADL shares on Sep 10, 2026, worth $2.5M.
Companies traded
Other insiders at CADL
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.2M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Tak Paul Peter made?
Tak Paul Peter has filed 1 SEC Form 4 filing (3 transaction rows) across 1 company since 2026.
Which companies does Tak Paul Peter trade?
Tak Paul Peter has filed SEC Form 4 disclosures for 1 company, including CADL.
When was Tak Paul Peter's most recent SEC Form 4 filing?
Tak Paul Peter's most recent SEC Form 4 filing on Tracefour is dated Sep 11, 2026.
What is Tak Paul Peter's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Tak Paul Peter is listed as Chief Executive Officer.
What is Tak Paul Peter's total buy and sell value in the current window?
Inside the rolling retention window, Tak Paul Peter bought $0 and sold $3.2M based on SEC Form 4 filings.
What was Tak Paul Peter's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 220,866 CADL shares on 2026-09-10, worth $2.5M, per SEC Form 4 filings.